Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MediMab Biotherapeutics Ltd is a ground-breaking biotherapeutic company focusing on the generation of novel immunotherapies for the treatment of cancer.  It uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumours. 

MediMabBio is a 100% owned subsidiary company of MediMabBio Inc. The subsidiary moved into the BioEscalator’s Innovation Lab in June 2020 to investigate unmet needs in cancer therapies. In February 2021, MediMabBio raised $18M in Series A funding from top-tier investors in South Korea to advance two immune-oncology pipelines (MMB 101 & MMB 102) towards the clinic.

CEOs & co-founders of the parent company (MediMabBio LLC.) Yu Hoi Kang and Hong Seok Jo worked and met at the Samsung Advanced Institute of Technology.  Dr Kang received her PhD from the University of Oxford before working on a post-doc project related to immune checkpoint inhibitors at Harvard Medical School.  Dr Jo obtained his PhD from KAIST (Korea Advanced Institute of Science and Technology) and has expertise in oncology, neurological disorders, biologics drug discovery and development. 

CEO of MediMab Biotherapeutics Ltd. Ji Eun Lee obtained her PhD in Biomedical Engineering from Imperial College London, and joined the company in March 2020.

For more information on MediMabBio visit;

https://www.bioescalator.ox.ac.uk/community/introducing-medimab-biotherapeutics-ltd

https://www.bioescalator.ox.ac.uk/news/medimabbio-raises-18m-series-a-funding